MicroRNA-130b promotes lung cancer progression via PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis

Jianwei Tian1†, Liping Hu1†, Xiao Li1,2†, Jian Geng3†, Meng Dai4 and Xiaoyan Bai1*

Abstract
Background: The prognosis of non-small-cell lung cancer (NSCLC) is poor yet mechanistic understanding and therapeutic options remain limited. We investigated the biological and clinical significance of microRNA-130b and its relationship with apoptosis in NSCLC.

Methods: The level of microRNA-130b in relationship with the expression of PPARγ, VEGF-A, BCL-2 and apoptosis were analyzed in 91 lung cancer patient samples using immunohistochemistry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay on tissue microarrays. Gain and loss-of-function studies were performed to investigate the effects of microRNA-130b, peroxisome proliferator-activated receptor γ (PPARγ) or vascular endothelial growth factor-A (VEGF-A) on biological functions of lung cancer cells using in vitro and in vivo approaches.

Results: MicroRNA-130b up-regulation conferred unfavorable prognosis of lung cancer patients. Notably, microRNA-130b targeted PPARγ and inhibiting microRNA-130b markedly repressed proliferation, invasion and metastasis of lung cancer cells, leading to increased apoptosis. MicroRNA-130b-dependent biologic effects were due to suppression of PPARγ that in turn activated BCL-2, the key mediator of anti-apoptosis. Administration of microRNA-130b mimic to mouse xenografts promoted tumor growth. In vitro and in vivo, miR-130b enrichment associated with down-regulation of PPARγ, up-regulation of VEGF-A and BCL-2, and decreased apoptosis.

Conclusions: The present study demonstrates that microRNA-130b promotes lung cancer progression via PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis. Targeting microRNA-130b might have remarkable therapeutic potential for lung cancer therapy.

Keywords: MicroRNA-130b, PPARγ, BCL-2, Apoptosis, NSCLC

Background
Several microRNAs (miRNAs), such as miR-21, miR-152, miR-148b and miR-208a, play critical roles in lung cancer progression through modulating growth, apoptosis, metastasis and invasion [1–4]. A recent study has identified microRNA-130 (miR-130) as a contributor in mesenchymal differentiation, hypoxic response modulation and tumorigenesis in colorectal cancer [5]. MiR-130b has also been documented in several other kinds of tumors, with up-regulation in melanoma [6], but down-regulation in endometrial cancer [7] and pituitary adenomas [8].

Peroxisome proliferator-activated receptor γ (PPARγ), acting as a tumor suppressor, exerts an essential role in modulating tumor proliferation, differentiation, apoptosis and invasion [9–11]. Combined treatment with the cyclo-oxygenase-2 (Cox-2) inhibitor niflumic acid and PPARγ ligand ciglitazone induces endoplasmic reticulum stress/caspase-8-mediated apoptosis in human lung cancer cells [12]. Treatment of human NSCLC lines with PPARγ ligands results in growth arrest, loss of capacity and induction of apoptosis [13]. Additionally, PPAR-response element (PPRE) has been identified in the human vascular endothelial growth factor-A (VEGF-A) promoter region [14] and PPARγ ligands have been
documented to down-regulate VEGF-A expression in prostate cancer [15]. VEGF-A up-regulation has been implicated in lung carcinogenesis [16] and correlates with apoptosis by driving the expression of BAX [17]. However whether VEGF-A interacts with BCL-2, a classical anti-apoptotic gene, in modulating lung cancer cell apoptosis remains unclear.

Studies have revealed that miR-130b promotes tumor aggressiveness by suppressing PPARγ but promotes VEGF-A expression and epithelial to mesenchymal transition (EMT) in hepatocellular [18] and colorectal cancer [5]. In terms of the correlations between PPARγ, VEGF-A and apoptosis, we hypothesize that miR-130b suppresses PPARγ and promotes lung cancer progression via VEGF-A/BCL-2-mediated inhibition of apoptosis. We also investigated the correlation between miR-130b expression and lung cancer patient’s prognosis and survival. Mechanisms of miR-130b/PPARγ-mediated apoptosis and lung cancer progression were also explored.

Methods
Patients and specimens
Total 91 NSCLC patients undergoing treatment in Nanfang Hospital in Guangzhou China from 2012 to 2015 were selected. This study was specifically approved by the Southern Medical University Ethics Committee. Informed consent was obtained from all individual participants included in the study. The overall survival time after tumor resection was 57.9 months (range 19–98 months). Specimens from these patients were obtained from the Department of Pathology and the Department of Thoracic Surgery in Nanfang Hospital. Thirty-six snap frozen fresh tumor samples and matched normal lung tissues (10 cm from the tumor) obtained from among the 91 specimens were also available for the study. Clinical pathologic characteristics of the patients were based on the World Health Organization criteria [19], as was described in Table 1.

Total RNA from tissues of lung cancer patients and healthy controls was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA). The synthetic oligonucleotide (3’-UUUCAUGUCGAUUUCAUUUCAUG-5’) non-existent in humans was spiked-in for quality control before miRNAs extraction according to the manufacturer’s instructions. The thermal cycle (Ct) values for a serial dilution of these miRNAs were assessed. All experiments were repeated in triplicate.

Immunolabeling
Tissue microarray construction, immunohistochemical staining and immunofluorescence co-labeling were carried out according to previously published procedures [20]. Briefly, samples were stained with the antibodies to PPARγ, VEGF-A and BCL-2 (Abcam, Cambridge) followed by EnVision/HRP Kit (Dako, Carpinteria, CA) and imaged with a BX51 light microscope (Olympus, Tokyo). The staining intensity was scored according to previously procedures [21].

Cell culture studies
A549 (adenocarcinoma) and H520 (squamous cell carcinoma) lung cancer cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and maintained in RPMI 1640 supplemented with 1 % penicillin/streptomycin and 10 % fetal bovine serum (FBS) in 5 % CO2, 37°C cell culture incubator.

Transfection of miRNA inhibitor and small interfering RNA
MiR-130b inhibitor (anti-M), miR-130b mimic, or the appropriate negative controls of miRNA inhibitor (anti-MC) and miRNA mimic were purchased from GenePharma (Shanghai, China). Anti-M and anti-MC were transfected at a final concentration of 50–100 nM in the cells using HiPerFect Transfection Reagent (Qiagen,
Hilden, Germany) according to the manufacturer’s recommendations. Expression of PPARγ and VEGF-A were knocked down with small interfering RNA (siRNA) duplexes using Oligofectamine (Invitrogen, Carlsbad, CA). The target sequences for PPARγ and VEGF-A mRNA were shown in Table 2. Non-targeting siRNA pool (D-001206-13-05; Dharmacon, Fisher Scientific, Pittsburgh, PA) was used as a negative control. Cells were harvested 72 hours post transfection for analysis.

Luciferase reporter assay
The predicted 3'-untranslated region (UTR) sequence of PPARγ and BCL-2 interacting with miR-130b and VEGF-A, respectively, and mutated sequences within the predicted target sites were synthesized and inserted into the pRL-TK control vector (Promega, Madison, WI). H520 cells transfected with 120 ng anti-miR-130b, VEGF-A siRNA or negative controls, followed by co-transfection with 30 ng of the wild-type or mutant 3'-UTR of the mRNA of PPARγ or BCL-2 using 0.45 μL of Fugene (Promega, Madison, WI). Luciferase assay was carried out using Dual-Luciferase Assay System (Promega, Madison, WI). Data were normalized by the ratio of firefly and Renilla luciferase activities measured at 48 h post-transfection.

Drug treatment
VEGF-A inhibitor (bevacizumab, 2.5 μM) and PPARγ inhibitor, GW9662 (20 μM, Sigma-Aldrich, St. Louis, MO) were used to treat A549 and H520 cells for 72 h and harvested for further analysis.

Cell proliferation assay
Cell proliferation analysis was performed in triplicate using a CellTiter 96 Non-Radioactive Cell Proliferation Assay Kit (Promega, Madison, WI) following the manufacturer’s protocols.

Cell migration assay
Cells (1.0 × 10^6 cells/ml) in serum-free medium were added to the top chamber of 24-well transwell plates (8 μm pore size; Corning Star, Cambridge, MA) and 600 μl of complete medium with 10 % FBS into the bottom chamber. The assembled chamber was incubated at 37 °C in a humidified, 5 % CO2 cell culture incubator for 24 h, fixed with 10 % formalin and stained with hematoxylin and eosin staining for visualization.

Cell invasion assay
Cells (5.0 × 10^4 cells/mL) were plated in 6-well plates and grown to over 90 % confluence. The monolayer of cells was scratched with a 200 μL pipette tip to create a wound gap, and treated with miR-130b inhibitor, siRNAs of PPARγ or VEGF-A, and control (0.1 % DMSO) at indicated time points. The same visual field was photographed using BX41 light microscope (10× objective) throughout the experiment. Wound closure was calculated as follows: Wound closure (%) = Gap (T-T0)/GapT0 × 100 % (where T is the treatment time and T0 is the time that the wound was induced).

In vitro plate-colony formation assay
Cells (200 cells/well) were plated in a six-well tissue culture plate and cultured for two weeks. Colonies with ≥50 cells were counted and plate colony formation efficiency was evaluated according to the following formula: number of colonies/number of cells inoculated) × 100 %. Triplicate samples from each group of cells were examined and colonies were counted by two individuals (XL and JG).

Apoptosis assay and cell cycle analysis using flow cytometry
Fixed cells were stained with the Annexin V-PE/7-AAD apoptosis kit (559763, BD Biosciences, Franklin Lakes, NJ) and apoptosis was evaluated by examining the percentage of apoptotic cells. Data acquisition and analysis were performed using Cell Quest software via a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ). The results were analyzed with the ModFit 3.0 software (Verity Software House, Topsham, ME). All experiments were repeated in triplicate.

TUNEL assay
Cells subjected to siRNA transfection or untreated cells were fixed with 4 % paraformaldehyde and detected using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay with an Apoptag Peroxidase in Situ Apoptosis Detection kit (Chemicon International, Temecula, CA) as described previously [22].

qRT-PCR analysis
qRT-PCR analysis was carried in triplicate with Power PCR SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA) using the ABI PRISM 7500 FAST Real-TIME PCR System (Applied Biosystems, Carlsbad, CA)

Table 2 Target sequences for PPARγ and VEGF-A mRNA

| Genes | Target sequences |
|-------|-----------------|
| PPARγ | 5'-AAUAUGACCGAUAGCUCCAAGAUAAG-3' |
| VEGF-A| 5'-TGCTGTGAAGATGTACTCTATCTCGTGTTTTGGCCACTGACTGACACGAGATAGTACATCTTCA-3' |
with results normalized to U6 or β-actin expression. The relative expression was calculated using the ΔΔCT method. Primer sequences used in qRT-PCR were listed in Table 3.

The specific miR-130b miScript Primer Assays (Qiagen, Hilden, Germany) were used for miRNA expression analysis. RNA was reverse transcribed using miRscript PCR System and analyzed by qRT-PCR with the miScript SYBR Green PCR Kit. MiR-130b levels were calculated as fold change \((2^{-\Delta\Delta CT})\) with respect to normal controls. The mean value of miR-130b expression in tumor tissues was calibrated to the levels detected in normal control tissues. Target-specific reverse transcription and Taqman microRNA assays were performed using the Hairpin-itTM miRNA qPCR Quantitation Kit (GenePharma, Suzhou) according to the protocol. The reactions were performed using the ABI PRISM 7500 FAST Real-TIME PCR System (Applied Biosystems, Carlsbad, CA). The relative expression of miR-130b was shown as fold difference relative to U6. The average value between 0.5 to 1.0 was regarded as miR-130b low and the value between 1.0 to 1.6 as miR-130b high. The 2^{-\Delta\Delta CT} method was used to calculate the relative expression. All experiments were performed in triplicate.

Western blot analysis and immunoprecipitation

Cell lysates from each experimental group were separated in parallel on two 10 % denaturing SDS-PAGE gels, transferred onto nitrocellulose membrane, blocked with 5 % non-fat milk in 0.1 % tris buffered saline with Tween-20 (TBST), and probed with antibodies to PPARγ, VEGF-A, and BCL-2, followed by incubation with appropriate secondary antibodies. The probed membrane was exposed and protein bands were visualized on X-ray films (Kodak X-OMAT BT, Rochester, NY). Immunoprecipitation was performed as previously described [23].

**In Vivo Studies of Tumorigenicity**

Male balb/c nude mice were kept in the Animal Center of Nanfang Hospital, Guangzhou, China according to the policies of the Committee for Animal Usage. To evaluate in vivo tumor growth, A549 cells with miR-130b mimic or appropriate controls (2 ng/mm3) were injected subcutaneously into the left flanks of ten mice. Thirty days after the injection, mice were euthanized and tumor growth was evaluated. Tumor volume \(\text{(mm}^3\)\) was calculated as \((W^2 \times L)/2\). Immunohistochemical staining for PPARγ, VEGF-A and BCL-2 were performed on mouse tissue specimens according to the previously mentioned method [21].

**Statistical analysis**

Data are expressed as mean ± standard deviation (SD) values. Correlations between expressions of miR-130b and PPARγ, VEGF-A and BCL-2 and lung cancer patients’ clinical pathological characteristics were analyzed using two-sided Fisher’s Exact Test. Pearson Correlation Analysis and Independent-Samples T Test were used to evaluate the correlation and differences between the expression of VEGF-A and PPARγ or BCL-2. Overall patient survival was calculated from the time of surgery to the time of death or to the time of last follow-up, at which point the data were censored. Kaplan-Meier method and a log-rank test were used to evaluate the difference between high and low miR-130b expression subgroups and the overall survival curves were generated. SPSS 13.0 (SPSS Inc., Chicago, IL) was used for all statistical analysis. A \(p < 0.05\) was regarded as statistically significant.

**Results**

**High miR-130b expression confers unfavorable prognosis of lung cancer patients**

To investigate whether miR-130b expression predicts patients’ prognosis, we examined miR-130b expression in tissues of lung cancer patients. We found increased miR-130b expression in lung cancer tissues compared with corresponding normal lungs. By qRT-PCR (Fig. 1a), low level of miR-130b was detected in 46 cases and high miR-130b expression was found in 45 cases. In lung cancer tissues, high miR-130b level corresponded with low PPARγ, high VEGF-A and BCL-2, and decreased apoptosis (Figs. 1b, c and d). Kaplan-Meier survival analysis demonstrated that patients with high miR-130b expression had a shorter overall survival time compared to patients with low miR-130b expression (Fig. 1e, 48.4 vs. 67.8 months, \(p < 0.001\)). Immunofluorescence co-labeling and Pearson correlation analysis (Fig. 2) revealed that PPARγ expression negatively correlated with VEGF-A \((r = -0.351, p = 0.001)\), and VEGF-A positively correlated with BCL-2 \((r = 0.328, p = 0.002)\). MiR-130b

| Genes | Forward primer | Reverse primer |
|-------|----------------|----------------|
| PPARγ | 5’-AGTAAAGAGCAGCTAGAAGACGGC-3’ | 5’-TCGGTTAAGGGCTGACTCTGTGGT-3’ |
| VEGF-A | 5’-TCACCAAGGCAGCACATAG-3’ | 5’-GAGGCTCCAGGGCATTAGA-3’ |
| BCL-2 | 5’-CATGACGACGGCAGCTCA-3’ | 5’-GAAATCAACAGGGGCGCACA-3’ |
| β-ACTIN | 5’-ATGATGATATCGCCGCGCTC-3’ | 5’-TCGATGGGGTACCTAGGCT-3’ |
expression associated with differentiation \((p = 0.002)\) and TNM stage \((p = 0.025)\) of lung cancer patients (Table 4). These results suggested that miR-130b could be used as a marker to predict lung cancer patients' prognosis.

**MiR-130b inhibition attenuates lung cancer cell aggressiveness via PPARγ/VEGF-A/BCL-2-mediated enhancement of apoptosis**

To decipher whether miR-130b promotes lung cancer progression and underlying mechanisms, we examined the effect of miR-130b inhibitor on the biological features of lung cancer cells and relationships with apoptosis. Inhibition of miR-130b increased PPARγ expression but decreased VEGF-A and BCL-2 as confirmed by immunofluorescence microscopy (Fig. 3a and b). Compared with negative controls, anti-miR-130b caused 23.7% increase in the mRNA level of PPARγ, but 47.3% and 43.2% reduction in VEGF-A and BCL-2 as detected by qRT-PCR (Fig. 3c). Western blot analysis demonstrated that anti-miR-130b increased the level of PPARγ by 65.2% but decreased
VEGF-A and BCL-2 by 60.8 % and 38.5 %, respectively (Fig. 3d). To further demonstrate that miR-130b targeted PPARγ in lung cancer cells, we investigated whether miR-130b interacted with the 3'-UTR of PPARγ mRNA using a dual-luciferase reporter assay. As shown, miR-130b depletion led to a significant increase in the luciferase activity of the wild-type reporter but not the mutant (Fig. 3e). A significantly slower proliferation rate was observed in lung cancer cells treated with anti-miR-130b compared with controls (Fig. 3f). MiR-130b depletion inhibited the ability of cells to invade (Fig. 3g), migrate (Fig. 3h) and form colonies (Fig. 3i). Anti-miR-130b caused 1.48-fold increase in the number of apoptotic cells compared with control cells by flow cytometric analysis (Fig. 3j). TUNEL assay revealed that miR-130b abrogation significantly enhanced apoptosis and caused 52.6 % increase in the apoptotic rate (Fig. 3k). Conversely, miR-130b mimic had the opposite effects (Additional file 1: Supplementary Figure). These results collectively suggested that miR-130b inhibition decreased lung cancer cell aggressiveness via PPARγ/VEGF-A/BCL-2-mediated enhancement of apoptosis.

**PPARγ silencing enhances lung cancer cell aggressiveness via VEGF-A/BCL-2-mediated suppression of apoptosis**

Next we knocked down PPARγ in lung cancer cells to investigate whether PPARγ mediated apoptosis through the VEGF-A/BCL-2 pathway and whether PPARγ had feedback regulation of miR-130b expression. We found that PPARγ silencing increased the expression of VEGF-A and BCL-2 as demonstrated by immunofluorescence...
microscopy (Fig. 4a and b). Compared with negative controls, PPARγ siRNAs (#1 and #2) decreased the mRNA level of PPARγ (46.1 and 39.5 %), but increased VEGF-A (23.8 and 21.3 %) and BCL-2 (12.1 and 11.3 %), respectively, as shown by qRT-PCR (Fig. 4c). PPARγ siRNAs (#1 and #2) decreased the protein level of PPARγ (87.4 and 89.8 %), but increased VEGF-A (89.9 and 88.7 %) and BCL-2 (86.8 and 85.9 %), respectively, as detected by Western blot analysis (Fig. 4d). A significantly faster proliferation rate and more Ki-67 positive cells were observed in PPARγ-silenced cells as compared with control cells (Fig. 4e and f). PPARγ silencing promoted anti-apoptosis (Fig. 4g) and migration ability (Fig. 4h) of lung cancer cells with increased ability to form colonies (Fig. 4i). PPARγ siRNAs caused significant decrease in the number of apoptotic cells (8.8 and 8.6 %) compared with control cells (11.9 %) by flow cytometric analysis (Fig. 4j). PPARγ silencing caused 58.3 and 54.7 % decrease in the cell apoptotic rate by TUNEL assay (Fig. 4k). However, PPARγ siRNAs had no effects on the expression level of miR-130b (Fig. 4l). These results suggested that PPARγ depletion promoted the aggressiveness of lung cancer cells through VEGF-A/BCL-2-mediated suppression of apoptosis. However, PPARγ did not have feedback regulation on miR-130b.

**Knockdown of VEGF-A reduces lung cancer cell aggressiveness via BCL-2-mediated activation of apoptosis in vitro**

To further investigate whether VEGF-A induced cell apoptosis via BCL-2 inhibition, VEGF-A siRNAs were used to knock down the expression of VEGF-A. Downstream gene expressions and biological features of cells were examined. Immunofluorescence microscopy revealed that VEGF-A siRNAs decreased the expression of BCL-2 and the two molecules co-localized with each other (arrowheads) (Fig. 5a). Compared with negative control cells, VEGF-A siRNAs (#1 and #2) decreased the mRNA level of VEGF-A (28.3 and 29.2 %) and BCL-2 (65.6 and 63.3 %), respectively, by qRT-PCR (Fig. 5b). VEGF-A siRNAs (#1 and #2) decreased the protein level of VEGF-A (48.8 and 49.4 %) and BCL-2 (88.1 and 60.8 %), respectively, by Western blot analysis (Fig. 5c). VEGF-A siRNAs led to a significant decrease in the luciferase activity of wt 3'-UTR of BCL-2 (Fig. 5d). Furthermore, VEGF-A siRNAs slowed cell growth (Fig. 5e and f), reduced the ability of cells to migrate (Fig. 5g), invade (Fig. 5h) and form colonies (Fig. 5i). VEGF-A siRNAs caused significant increase in the number of apoptotic cells (17.0 and 17.3 %) as detected by flow cytometric analysis (Fig. 5j) and 30.5 and 28.1 % increase in the apoptotic rate by TUNEL assay (Fig. 5k). However, VEGF-A siRNAs had no effects on miR-130b expression (Fig. 5l). These results demonstrated that VEGF-A silencing induced cell apoptosis via inhibition of BCL-2. However, VEGF-A had no feedback regulation on miR-130b in lung cancer cells.

**PPARγ antagonism abolishes the effect of miR-130b inhibition on VEGF-A/BCL-2-mediated apoptosis**

To further explore whether miR-130b targets PPARγ in mediating apoptosis, we treated lung cancer cells with PPARγ antagonist GW9662 and examined the downstream effects. Western blot analysis demonstrated that anti-miR-130b up-regulated the expression level of PPARγ but down-regulated VEGF-A and BCL-2. GW9662 abolished the effect of miR-130b inhibition on the expression of VEGF-A and BCL-2 (Fig. 6a). Treatment with VEGF-A inhibitor bevacizumab (2.5 μM) down-regulated the expression of BCL-2 in a time-dependent manner (Fig. 6b) and dose-dependent manner (Fig. 6c). Immunoprecipitation analysis revealed that bevacizumab significantly inhibited the interaction between PPARγ and VEGF-A upon miR-130b inhibition (Fig. 6d), suggesting that VEGF-A acted as the downstream of PPARγ in mediating the cascade of events. Further studies also demonstrated that VEGF-A interacted with BCL-2 upon PPARγ inhibition (Fig. 6e). Flow cytometric analysis

---

Table 4: Correlation between MiR-130b and patient clinicopathological characteristics

| Items               | MiR-130b (N = 91) | p    |
|---------------------|-------------------|------|
|                     | Low (N = 46)      | High (N = 45) | |
| Gender              |                   |      | |
| Male                | 19                | 19   | 0.929 |
| Female              | 27                | 26   |      |
| Smoking Status      |                   |      | 0.303 |
| Nonsmoker           | 12                | 7    |      |
| Smoker              | 34                | 38   |      |
| Tumor Location      |                   |      | 0.327 |
| Central             | 21                | 16   |      |
| Peripheral          | 25                | 29   |      |
| Differentiation     |                   |      | 0.002 |
| High                | 31                | 16   |      |
| Moderate-Poor       | 15                | 29   |      |
| LN Metastasis       |                   |      | 0.026 |
| Yes                 | 33                | 22   |      |
| No                  | 13                | 23   |      |
| Tumor Size          |                   |      | 0.002 |
| >3 cm               | 36                | 21   |      |
| <3 cm               | 10                | 24   |      |
| TNM Stage           |                   |      | 0.025 |
| I-II                | 25                | 14   |      |
| III-IV              | 21                | 31   |      |

*p values listed are derived from χ² test*
(Fig. 6f, upper panels) and the TUNEL assay (Fig. 6f, middle panels) demonstrated that PPARγ antagonist GW9662 attenuated the effect of miR-130b inhibition on VEGF-A/BCL-2-mediated apoptosis (Fig. 6f, lower panels). Taken together, these results suggested that PPARγ functioned as a critical regulator in miR-130b mediated lung cancer apoptosis through the VEGF-A/ BCL-2 pathway.
MiR-130b promotes tumor growth and suppresses apoptosis via PPARγ/VEGF-A/BCL-2 signaling in mouse xenografts

To investigate the effect of miR-130b on tumor growth in vivo, miR-130b mimic or controls was injected subcutaneously into the mouse. We found that miR-130b mimic significantly increased the tumor volume of A549 mouse xenografts compared with controls in one month time (Fig. 7a and b). MiR-130b mimic decreased the protein level of PPARγ and BCL-2, respectively.
PPARγ by 51.7%, but increased VEGF-A and BCL-2 by 41.3 and 52.6%, respectively, confirmed by immunohistochemistry (Fig. 7c) and quantification of the staining intensity (Fig. 7d). MiR-130b mimic reduced the apoptotic rate by 52.6% (Fig. 7e), decreased PPARγ mRNA level by 53.3%, increased VEGF-A and BCL-2 by 62.8 and 49.3%, respectively, as detected by qRT-PCR (Fig. 7f). MiR-130b mimic decreased PPARγ protein level by 87.2%, but increased VEGF-A and BCL-2 by 96.4 and 90.1%, respectively, by Western blot analysis (Fig. 7g). These data confirmed the in vitro findings and further supported the
The present study indicates that miR-130b increases the expression of VEGF-A and BCL-2 but suppresses PPARγ signaling.

**Discussion**

The present study indicates that miR-130b increases the expression of VEGF-A and BCL-2 but suppresses PPARγ signaling.
and apoptosis. Importantly, we demonstrate that VEGF-A targets BCL-2 and promotes the aggressiveness of lung cancer cells via BCL-2-mediated suppression of apoptosis. These data highlight the critical role of miR-130b in promoting lung cancer progression through PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis (Fig. 8).

Furthermore, immunoprecipitation demonstrates the interaction between PPARγ and VEGF-A, supporting the notion that miR-130b plays a critical role in regulating lung cancer cell aggressiveness and apoptosis through the PPARγ/VEGF-A axis. However, neither PPARγ nor VEGF-A siRNAs had feedback regulatory effects on the miR-130b expression. This suggests that miR-130b acts as the upstream of the PPARγ/VEGF-A axis in mediating apoptosis and downstream gene expressions.

Fig. 7 MiR-130b promotes tumor growth and suppresses apoptosis via PPARγ/VEGF-A/BCL-2 signaling in A549 mouse xenograft. a and b Larger tumor volume treated with miR-130b mimic compared with the control at day 30. c MiR-130b mimic decreased PPARγ and apoptosis, but increased VEGF-A and BCL-2 in A549 generated xenografts by immunohistochemistry (upper panels) and TUNEL assay (lower panel). d Quantification analysis of the staining intensity and cell apoptotic rate. e and g MiR-130b mimic decreased the level of PPARγ in A549-generated xenografts, but increased VEGF-A and BCL-2. Scale bar, 50 μm. CTRL: control; TUNEL, terminal deoxynucleotidyl transferase-mediated uridine 5’-triphosphate-biotin nick end labeling. Each bar represents the mean ± SD. Results are representative of three independent experiments. *p < 0.05, #p < 0.001.
Studies have demonstrated that miR-130b suppresses migration and invasion of colorectal cancer cells through downregulation of Integrin-β1 [24]. MiR-130b may promote hepatocellular carcinoma cell migration and invasion by inhibiting PPARγ and subsequently inducing EMT [18, 25]. MiR-130b also plays an important pro-fibrotic role in skin fibrosis and enhances TGF-β signaling through repression of PPARγ [26]. Moreover, varied expression levels of miR-130b have been found in endometrial [27], gastric [28] and bladder [29] cancer regulating different signaling molecules. We found that miR-130b, by targeting PPARγ, promotes aggressiveness through VEGF-A-mediated suppression of apoptosis in lung cancer. These studies demonstrate that miR-130b plays a role in regulating tumor progression.

Functionally, our data indicate that miR-130b not only exhibits a potent oncogenic role, in agreement with other recent reports [30], but also suppresses lung cancer cell apoptosis through VEGF-A-mediated up-regulation of BCL-2, the classical anti-apoptotic gene. In addition, knocking down VEGF-A caused a significant reduction in BCL-2 protein levels and decreased luciferase activity. These results further suggest that VEGF-A interacts with BCL-2 in mediating lung cancer cell apoptosis. It has been demonstrated that in wild-type p53 expressing cells, miR-130b directly represses Zinc finger E-box-binding homeobox 1 (ZEB1), opposing EMT and invasive phenotypes. However, in the context of gain-of-function p53 mutations, mutant p53 triggers EMT by indirectly inducing ZEB1 expression through negative regulation of miR-130b [27]. Undoubtedly, miR-130b exerts a critical function in regulating cell apoptotic processes. Our results have revealed for the first time that miR-130b, through up-regulating the BCL-2 signaling, enhances lung cancer progression and inhibits cell apoptosis. Future studies exploring the significance of circulating miR-130b in lung cancer development and progression may provide possible evidences for early detection and targeting of lung cancer risk factors. Our results have shown that miR-130b promotes lung cancer progression through PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis.

Lines of evidence have demonstrated the link between miRNA dysregulation with malignant transformation in a variety of cancers [31–33]. Previous report [34] and our present results identify miR-130b as an important signature in lung cancer. MiR-130b up-regulation has been detected in lung adenocarcinoma and squamous cell carcinoma and confers advanced tumor stage, poor differentiation and unfavorable prognosis of lung cancer patients. This is in line with other studies showing that miR-130b up-regulation correlates with the clinical stage of gastric [35] and esophageal carcinoma [30]. However, we found that in lung cancer tissues, cases with high miR-130b expression level did not correlate positively with lymph node metastases and larger tumor size. We assume that factors, like the tumor microenvironment or other growth factors, also contributed to the lymph node metastasis and growth of lung tumors. In addition, this could also be in part due to the limited sample size analyzed in the present study, which needs further investigations in expanded samples.

Conclusions

We demonstrate that miR-130b targets PPARγ and suppresses lung cancer cell apoptosis through the VEGF-A/BCL-2 pathway. High miR-130b expression confers
unfavorable prognosis of lung cancer patients. These findings indicate clinical values of our study and that miR-130b is a potential new therapeutic target for lung cancer diagnosis and treatment.

Additional file

Additional file 1: MiR-130b mimic enhances lung cancer cell aggressiveness via PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis. (A) Representative images of A549 cells treated with miR-130b mimic and co-labeled for PPARγ (green) and VEGF-A (red) (scale bar, 50 μm), (B) Representative images of A549 cells treated with miR-130b mimic and labeled for BCL-2 (green) (scale bar, 50 μm). (C and D) MiR-130b mimic decreased PAPP, but increased VEGF-A and BCL-2. (E) MiR-130b mimic caused a significant decrease in the luciferase activity of wt 3' UTR of PAPP. (F) A faster proliferation rate in cells treated with miR-130b mimic compared with controls. (G) Increased number of invaded cells with miR-130b mimic treatment (scale bar, 100 μm). (H) Longer migrated distance in cells treated with miR-130b mimic at indicated time points. (I) Increased colonies in cells treated with miR-130b mimic at 48 hours time point. (J) Decreased apoptotic cells treated with miR-130b mimic compared with controls. (K) Decreased apoptotic rate in cells treated with miR-130b mimic (scale bar, 50 μm). NC: normal control; miR-NC: miR-130b control; miR-130bm: miR-130b mimic; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling: VEGF-A, vascular endothelial growth factor-A; ZEB1, zinc finger E-box-binding homeobox 1.

Abbreviations
AD, adenocarcinoma; anti-Mi, anti-miR-130b; anti-MC, anti-miR-130b control; EMT, epithelial to mesenchymal transition; miR-130b, microRNA-130b; NL, normal lung; NSCLC, non-small-cell lung cancer; NT siRNA, non-targeting small interference RNA; PAPP, peroxisome proliferator-activated receptor; PPRE, PPAR-response element; SD, standard deviation; SQ, squamous cell carcinoma; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; VEGF-A, vascular endothelial growth factor-A; ZEB1, zinc finger E-box-binding homeobox 1.

Acknowledgements
This study was supported by National Nature and Science Young Investigator Grant (no. 81100496) from the National Natural Science Foundation of China, Matching Grant (no. G201203) of the National Natural Science Foundation of China from Nanfang Hospital, Southern Medical University, Guangdong Natural Science Foundation (no. 2016A030303081) and Distinguished Young Scholar Fund from Nanfang Hospital (2015), 2009 to YJ.

Authors’ contributions
XH and LH contributed to conception and design, data analysis and manuscript writing. JT and MD performed the immunostaining and flow cytometry. All authors reviewed the manuscript and approved the final authorship.

Competing interests
The authors declare that they have no competing interests.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. Informed consent was obtained from all individual participants included in the study.

Author details
1 State Key Laboratory for Organ Failure Research, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China. 2Department of Emergency, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. 3Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. 4Health Management Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Received: 17 January 2016 Accepted: 22 June 2016
Published online: 01 July 2016

References
1. Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, Liu SH, Yi QT, Li J, Song CH. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small-cell lung cancer screening. Tumour Biol. 2015;36(4):3053.
2. Tang Y, Cui Y, Li Z, Zhao Z, Yang Y, He Y, Chen G, Zhu Y, Wang X, Zhou X, Luo J, Zhang S. Radiation-induced miR-20bA in lineage-specific sensitization and radioresistance by targeting P21 in human lung cancer cells. J Clin Cancer Res. 2016;35:7.
3. Chi Y, Zhou D. MicroRNAs in colorectal carcinoma—from pathogenesis to therapy. J Exp Clin Cancer Res. 2016;35:43.
4. Gurtner A, Falcone E, Garibaldi R. Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res. 2016;35:43.
5. Colangelo T, Fucci A, Vittori CE, Lepri T, Pancione M, Laudanna C, Biasini M, Bigianni E, Ferrante C, Forte N, Calonius V. MicroRNA-130b oncogene: tumor development and is associated with poor prognosis in colorectal neoplasia. PLoS Pathog. 2013;15(10):2188–31.
6. Kunz M, MicroRNAs in melanoma biology. Adv Exp Med Biol. 2013;774:103–20.
7. Li BL, Li Y, Zhang J, Feng Q, Qu L, Hong X, Wan XP. miR-130b is an EMT-related microRNA that targets Dicer1 for aggression in endometrial cancer. Med Oncol. 2015;32(1):84.
8. Leone V, Lampella C, D’Angelo E, Musmeci P, Weierick A, Terracciano L, Li V, Lechler R, Rotondi J, Jaffrain-Rea ML, Trouillas J, Fusco A. MiR-23b and miR-130b expression is downregulated in pituitary adenomas. Mol Cell Endocrinol. 2014;390(1–2):1–7.
9. Fujii K, Kato S, Nakamura M, Ohno M, Hashimoto T, Kondo A, Shiga T, Hayashi K, Shiga T, Tsuchiya M, Baba Y, Oki E, Morita M, Shiose Y, Baba H. Small molecule agonists of PPAR-gamma exert therapeutic effects in esophageal cancer. Cancer Res. 2014;74(2):575–85.
10. Tan BS, Kang O, Mai CW, Wong KH, Kho A, Pichka MR, Bhardwaj T, Leong CO. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor gamma (PPARgamma). Cancer Lett. 2013;336(1):127–39.
11. Li S, Zhou Q, He H, Zhao Y, Liu Z. Peroxisome proliferator-activated receptor gamma agonists induce cell cycle arrest through transcriptional regulation of Kruppel-like factor 4 (KLK4). J Biol Chem. 2013;288(6):4076–84.
12. Kim BM, Maeng K, Lee KH, Hong SH. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARgamma ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett. 2011;302(2):134–44.
13. Walther U, Emmrich K, Ramer R, Mittag N, Hinz B. Lovastatin lactone elicits angiogenesis inhibitor 2 expression in prostate cancer cells: implications for antiangiogenesis therapy. Oncotarget. 2016;7(10):10345–62.
14. Hasan AU, Ohmori K, Konishi K, Igarashi J, Hashimoto T, Kamitori K, Yamaguchi F, Tsukamoto I, Uyama T, Ishihara Y, Noma T, Tokuda M, Kohno M. Eicosapentaenoic acid upregulates VEGF-A through both GPR120 and PPARgamma-mediated pathways in 3 T3-L1 adipocytes. J Biol Chem. 2013;288(6):4076–84.
15. Kim BM, Maeng K, Lee KH, Hong SH. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARgamma ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett. 2011;302(2):134–44.
16. Walther U, Emmrich K, Ramer R, Mittag N, Hinz B. Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARgamma-dependent pathway. Oncotarget. 2016;7(9):10345–62.
17. Hasan AU, Ohmori K, Konishi K, Igarashi J, Hashimoto T, Kamitori K, Yamaguchi F, Tsukamoto I, Uyama T, Ishihara Y, Noma T, Tokuda M, Kohno M. Eicosapentaenoic acid upregulates VEGF-A through both GPR120 and PPARgamma-mediated pathways in 3 T3-L1 adipocytes. Mol Cell Endocrinol. 2015;406:10–8.
18. Qin L, Ren Y, Chen AM, Guo FJ, Xu F, Gong C, Cheng P, Du YL. Peroxisome proliferator-activated receptor gamma ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway. Mol Med Rep. 2014;10(1):276–82.
19. Schwaederle M, Lazar V, Valdeire P, Hanson J, Lacrovier L, Soria JC, Pawitan Y, Kurokawa M, Lazar V, Valdeire P, Hanson J, Lacrovier L, Soria JC, Pawitan Y, Kurokawa M. Lovastatin lactone elicits angiogenesis inhibitor 2 expression in prostate cancer cells: implications for antiangiogenesis therapy. Oncotarget. 2016;7(5):1187–90.
20. Dai G, Tong Y, Chen X, Ren Z, Ying Y, Yang F, Chai K. Myricanl induces apoptotic cell death and anti-tumor activity in non-small cell lung carcinoma in vivo. Int J Mol Sci. 2015;16(2):2717–31.
21. Tu K, Zheng X, Dou C, Li C, Yang W, Yao Y, Liu Q. MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma. Int J Mol Sci. 2014;15(11):20486–99.
19. Li X, Wan L, Shen H, Geng J, Nie J, Wang G, Jia N, Dai M, Bai X. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol. 2012;7(1):76–84.

20. Li X, Wan L, Geng J, Wu CL, Bai X. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol. 2012;7(8):1235–45.

21. Geng J, Li X, Zhou Z, Wu CL, Dai M, Bai X. EZH2 promotes tumor progression via regulating VEGF-A/PIK3 signaling in non-small cell lung cancer. Cancer Lett. 2015;359(2):275–87.

22. Bai X, Geng J, Li X, Yang F, Tian J. VEGF-A inhibition ameliorates podocyte apoptosis via repression of activating protein 1 in diabetes. Am J Nephrol. 2014;40(6):523–34.

23. Bai X, Li X, Tian J, Zhou Z. Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes. PLoS One. 2014;9(4):e96117.

24. Zhao Y, Miao G, Li Y, Isaji T, Gu J, Li J, Qi R. MicroRNA-130b suppresses migration and invasion of colorectal cancer cells through downregulation of integrin beta1 [corrected]. PLoS One. 2014;9(2):e87938.

25. Lin YH, Wu MH, Liao CJ, Huang YH, Chi HC, Wu SM, Chen CY, Tseng YH, Tsai CY, Chung IH, Tsai MM, Shih WH, Lin KH. Repression of microRNA-130b by thyroid hormone enhances cell motility. J Hepatol. 2015;63(5):827–36.

26. Luo H, Zhu H, Zhao B, Xiao X, Zuo X. MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor gamma. Mod Rheumatol. 2015;25(4):595–602.

27. Dong P, Karayaev M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J, Sakuragi N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32(27):3286–95.

28. Kim BH, Hong SW, Kim A, Chei SH, Yoon SO. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 2013;107(5):505–10.

29. Egawa H, Jingushi K, Hirono T, Ueda Y, Kitae K, Nakata W, Fujita K, Uemura K, Nonomura N, Tsujikawa K. The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN. Sci Rep. 2016;6:20574.

30. Yu T, Cao R, Li S, Fu M, Ren L, Chen W, Zhu H, Zhan Q, Shi W. miR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells. BMC Cancer. 2015;15:52.

31. Liu M, Zhou K, Huang Y, Cao Y. The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the PI3K/AKT pathway. J Exp Clin Cancer Res. 2015;34:121.

32. Jiang B, Mu W, Wang J, Lu J, Jiang FX, Li L, Xie W, Tian H. MicroRNA-138 functions as a tumor suppressor in lung cancer by targeting differentiated embryonic chondrocyte gene 2. J Exp Clin Cancer Res. 2016;35(1):169.

33. Mitra R, Edmonds MD, Sun J, Zhao Z, Yu H, Eschen CM, Zhao Z. Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer. RNA. 2014;20(9):1356–68.

34. Ibarrola-Villava M, Llorca-Cardenosa MJ, Tarazona N, Mongiot C, Fleitas T, Perez A, Espinola A, Navarro S, Ribas G, Cervantes A. Deregulation of AKT1, ID2, ID4, and PIK3CA and target-related microRNA expression in glioblastoma multiforme. J Clin Oncol. 2015;33(29):26935–45.